Navigation Links
SleepQuest Compliance Again Doubles Industry Average
Date:2/3/2009

Study Shows Patients Consistently Adhere to Sleep Apnea Treatment

SAN CARLOS, Calif., Feb. 3 /PRNewswire/ -- SleepQuest announced today that an internal study has shown their patients comply with Obstructive Sleep Apnea treatment at a rate nearly twice the industry average.

Analysis performed in October 2008 looked at Northern California patients who received home sleep testing and treatment with Positive Airway Pressure beginning in early 2008. Of the patients surveyed, 91% were compliant, while known industry standards are closer to 50%. This percentage is based on the average number of treatment hours for patients using CPAP more than four hours per night.

"Compliance is dependent upon the caregiver's expertise with the many different complications that might occur with PAP treatment," said Robert Koenigsberg, SleepQuest President/CEO. "Our resolute focus is to troubleshoot problems that patients may experience and to find the right solutions for them."

Obstructive Sleep Apnea (OSA) is a dangerous condition in which soft tissues in the throat collapse during sleep, triggering a partial awakening to prevent suffocation. During PAP treatment (Continuous, Bi-level and AutoPAP), the patient receives positive air flow via a mask or nasal interface that keeps the airway open, allowing regular, quiet breathing and restful sleep to occur. Patients frequently have a hard time adjusting to treatment. Trial and error is often required to find the right combination of facial interface type, the most appropriate PAP device, and air flow settings that are most comfortable. If patients find it unpleasant, difficult to operate, or ineffective, they may lose interest in adhering to treatment.

"Most providers of CPAP therapy are general home care companies," said Lori Schulman, SleepQuest's Director of Contracting. "They focus on providing 1500 different products aimed at 150 different dise
'/>"/>

SOURCE SleepQuest
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. SleepQuest Achieves Coveted Accreditation
2. SleepQuest Tireless in Pursuit of Good Sleep
3. Latest Sleep Disorder Technology Tested With SleepQuest
4. SleepQuest to Open San Francisco Office
5. SleepQuest Raises Awareness of Sleep Disorders
6. SleepQuest Launches Updated Web Site
7. Level 3 Inspection Achieves 100% Compliance in ISO 9001 & AS 9100 Certification
8. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
9. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
10. MicroDose and Nexus6 Announce Collaboration to Evaluate Application of Remote Patient Compliance Monitoring Technology with MicroDoses Electronic Dry Powder Inhaler
11. NYSE Alternext US Accepts China Shenghuos Compliance Plan for Continued Listing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  Array BioPharma Inc. (NASDAQ: ... definitive agreement with Novartis Pharma AG to acquire worldwide ... Phase 3 development.  This agreement is conditional on the closing ... on April 22, 2014, which are expected to close in ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 GEA Niro ... table top laboratory homogenizer, the PandaPLUS 2000, which is ... nanoemulsions , and cell disruption . This compact ... products, fruit juices, liquid food, food additives and ingredients ...
(Date:1/22/2015)... / Rootstown, OH (PRWEB) January 22, 2015 ... platform, announced today that it has received AOAC-PTM Certifications for ... O1O3, O111, O121, and O145; collectively referred to as STEC ... O157, at 1 colony forming unit (cfu) per 325 g ...
(Date:1/22/2015)... 22, 2015 Selexis SA, a serial ... Cell Banks (RCBs) used for drug discovery to commercial ... will include Next-Generation Sequencing (NGS) data packages. ... biologic manufacturing by ensuring the integrity of the gene, ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2
... Non-GAAP EPS Increased 22 Percent, CAMBRIDGE, Mass., April 23 ... the first quarter of,2008, which featured excellent revenue growth, continued ... the company., First-Quarter Highlights -- Total revenue ... $883.2 million in same period a ...
... Cardiac Science,Corporation (Nasdaq: CSCX ), a ... informatics products, announced today,that it will release its ... 2008 after the market close. The Company has ... 4:30 p.m. Eastern Time to,discuss the financial results ...
... image are better than one for analyzing tumors , ... determine the amount of oxygen in a tumor very useful, because ... a poor outcome. A new method to do this and to ... been developed and used to image tumors in mice by Murali ...
Cached Biology Technology:Genzyme Reports Strong First-Quarter Growth 2Genzyme Reports Strong First-Quarter Growth 3Genzyme Reports Strong First-Quarter Growth 4Genzyme Reports Strong First-Quarter Growth 5Genzyme Reports Strong First-Quarter Growth 6Genzyme Reports Strong First-Quarter Growth 7Genzyme Reports Strong First-Quarter Growth 8Genzyme Reports Strong First-Quarter Growth 9Genzyme Reports Strong First-Quarter Growth 10Genzyme Reports Strong First-Quarter Growth 11Genzyme Reports Strong First-Quarter Growth 12Genzyme Reports Strong First-Quarter Growth 13Genzyme Reports Strong First-Quarter Growth 14Genzyme Reports Strong First-Quarter Growth 15Genzyme Reports Strong First-Quarter Growth 16Genzyme Reports Strong First-Quarter Growth 17Genzyme Reports Strong First-Quarter Growth 18Genzyme Reports Strong First-Quarter Growth 19Cardiac Science Schedules First Quarter Earnings Release and Announces Conference Call 2JCI table of contents: April 22, 2008 2JCI table of contents: April 22, 2008 3JCI table of contents: April 22, 2008 4JCI table of contents: April 22, 2008 5JCI table of contents: April 22, 2008 6JCI table of contents: April 22, 2008 7JCI table of contents: April 22, 2008 8JCI table of contents: April 22, 2008 9JCI table of contents: April 22, 2008 10JCI table of contents: April 22, 2008 11JCI table of contents: April 22, 2008 12
(Date:1/22/2015)... Jan. 16, 2015  A man-made form of insulin delivered ... mental capabilities in adults with mild cognitive impairment and ... by researchers at Wake Forest Baptist Medical Center. ... amnesic mild cognitive impairment (MCI) or mild to moderate ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) ... Wearable Technologies Market and Applications, Opportunities, Industry Analysis, ... 2014-2020" report to their offering. , ... can be worn on the user,s body and ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... addition of the "The Global Watermarking and ... http://photos.prnewswire.com/prnh/20130307/600769 ... digital media watermarking and fingerprinting markets. Watermarking aims ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2The Global Watermarking and Fingerprinting Markets 2
... first time, researchers have developed a way to synthesize a ... it works. , Derived from a fungus discovered clinging to ... certain cancer cells into suicide while leaving healthy cells untouched. ... might have some tremendous potential as a prototype anticancer agent, ...
... cell count" burst into the world's medical vocabulary as ... The public began to understand the crucial importance of ... infection and guarding against future attacks. , While scientists ... diseases, one area has remained murky: disorders caused by ...
... together, and most people find it impossible to tell ... just about everything, including their genes. But sometimes only ... both of them should. , Scientists at the University ... how two people who are so similar biologically can ...
Cached Biology News:New lab technique churns out fungus' potential cancer fighter 2Researchers add crucial information on how the body's T cells react to parasitic diseases 2Researchers add crucial information on how the body's T cells react to parasitic diseases 3How can identical twins be genetically different? 2How can identical twins be genetically different? 3
... personal-sized Thermal Cycler is the ideal instrument for ... range of PCR applications. Get Applied ... Save lab space without sacrificing results. ... Industry-Standard PCR Technology You Can Afford ...
... upgraded micro 10 represents a major advance ... of the benefits of large robotic liquid ... benchtop dispenser. Dispensing accurate volumes ranging from ... 10 has unique advantages not yet found ...
This free-standing laminar flow hood provides a horizontal flow of HEPA-filtered air to create a clean processing area. Air return slots along the front and side edges of the work area enhance system...
... Motic's B3 series of microscopes offer all ... required for laboratory work. Equipped with Koehler ... Contrast (ASC) objectives. The B3 is the ... Siedentopf binocular tube eliminates the need for ...
Biology Products: